The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ICML 2019 | Moving towards chemo-free regimens in CLL

Name: Moving towards chemo-free regimens in CLL
Uploaded: 2019-06-19T00:00:00.000Z
Duration: 1 min 42 s
Description: Michael Hallek, MD, PhD, University of Cologne, Cologne, Germany, discusses the emergence of chemotherapy-free regimens in chronic lymphocytic leukemia (CLL), highlighting the situtations where this approach wouldn't be used. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Michael Hallek • 19 Jun 2019

ICML 2019

Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab Venetoclax

CLL14

Michael Hallek, MD, PhD, University of Cologne, Cologne, Germany, discusses the emergence of chemotherapy-free regimens in chronic lymphocytic leukemia (CLL), highlighting the situtations where this approach wouldn’t be used. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.